Clinical trials: Adenocarcinoma Metastatic
Renal Cell Carcinoma
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
This is a multi-national, phase II, single arm study to explore the safety/efficacy and potential biomarkers on sunitinib 2/1 schedule for Asian patients with advanced renal cell carcinoma.
- Trial name
- NCT02626754
- Testing
- Sunitinib malate
- Where
- 7 sites in Taiwan
- Volunteers
- 13 people
- Sponsor
- vghtpe user
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or…
- Trial name
- NCT05363631
- Testing
- Selenomethionine (SLM), Axitinib, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fernando Maciel Barbosa
Bile Duct Adenocarcinoma
Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
This is an open-label, single-arm, multicenter Phase II clinical study to evaluate the efficacy and safety of surufatinib combined with cardanilimab in second-line treatment of patients with inoperable or metastatic bile duct…
- Trial name
- NCT06092645
- Testing
- surufatinib plus cadonilimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Renal Cell Carcinoma
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
This is an open-label, multi-center study to evaluate the safety of RAD001 in Chinese patients with metastatic renal cell cancer who are intolerant of or have progressed despite treatment with vascular endothelial growth factor…
- Trial name
- NCT01152801
- Testing
- Everolimus (RAD001)
- Where
- 7 sites in China
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Cancer, Prostate Cancer
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01160705
- Testing
- docetaxel, RNA analysis, reverse transcriptase-polymerase chain reaction
- Where
- 5 sites in Ireland
- Volunteers
- 73 people
- Sponsor
- Cancer Trials Ireland
Kidney Cancer
Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Tretinoin may help kidney cancer cells develop into normal cells. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00003656
- Testing
- recombinant interferon alfa, tretinoin liposome
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Renal Cell Carcinoma, Circulating Tumor Cell
Circulating Tumor Cell Reducing No-touch Nephrectomy
This study will study circulating tumor cell (CTC) release during laparoscopic radical nephrectomy (LRN) for RCC. The main objective is to determine if CTC release can be reduced during RN by using a no-touch technique, with an…
- Trial name
- CITO-CERENE (NCT05070637)
- Testing
- No-touch laparoscopic radical nephrectomy, Conventional laparoscopic radical nephrectomy, Laparoscopic total nephrectomy control arm
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Hospital de Santa Maria, Portugal
Breast Cancer, Breast Adenocarcinoma
Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.
- Conditions
- Breast Cancer, Breast Adenocarcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Recurrent Breast Carcinoma
- Trial name
- NCT02824575
- Testing
- Rebastinib, Paclitaxel, Eribulin Mesylate
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Montefiore Medical Center
Colorectal Cancer
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer
This 2 arm study assessed the efficacy and safety of maintenance treatment with Avastin (bevacizumab) + Xeloda (capecitabine), after initial treatment with Xeloda + oxaliplatin + Avastin, in patients with metastatic colorectal…
- Trial name
- NCT00623805
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Gastric Adenocarcinoma, Gastric Cancer
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Background: Three-fourths of people diagnosed with gastric cancer will die from it. Researchers want to see if giving cancer drugs in a new way can help people live longer and delay the time it takes for the cancer to grow.
- Conditions
- Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
- Trial name
- NCT04034251
- Testing
- Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.
- Trial name
- NCT01354431
- Testing
- nivolumab
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 168 people
- Sponsor
- Bristol-Myers Squibb
Malignant Solid Tumour, Gastroesophageal Cancer
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
This study is a Phase I/II trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors. In Phase I the Maximum Tolerated Dose (MTD) will be determined; in Phase II patients with first-line metastatic…
- Trial name
- NCT01611857
- Testing
- Tivantinib, FOLFOX
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- SCRI Development Innovations, LLC
Gastroesophageal Adenocarcinoma, First Line Therapy
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA).
- Conditions
- Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer, PDL-1
- Trial name
- ZANGEA (NCT07176312)
- Testing
- Zanidatamab, Pembrolizumab, mFOLFOX
- Where
- 20 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Solid Tumor, Solid Carcinoma
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV)…
- Conditions
- Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer
- Trial name
- MAST (NCT05346484)
- Testing
- CF33-hNIS, Pembrolizumab, Modified FOLFOX
- Where
- 12 sites in United States, Australia
- Volunteers
- 66 people
- Sponsor
- Imugene Limited
Metastatic Melanoma, Advanced Locoregional Melanoma
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma.
- Conditions
- Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
- Trial name
- NCT05155033
- Testing
- Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Adenocarcinoma
Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation
This is an open-label Phase I trial designed to determine the phase 2 recommended dose (RP2D) of belinostat in combination with nivolumab with or without ipilimumab.
- Trial name
- BENEFIT (NCT04315155)
- Testing
- Belinostat, nivolumab, ipilimumab
- Sponsor
- University of Utah
Pancreatic Cancer, Metastatic Pancreatic Cancer
Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
In this study, clinical data of patients who received 2nd-line Nab-paclitaxel plus Gemcitabine (nab-P+GEM) after progression on 1st-line FOLFIRINOX will be reviewed retrospectively.
- Trial name
- NCT04133155
- Testing
- nab paclitaxel plus gemcitabine
- Where
- South Korea
- Volunteers
- 103 people
- Sponsor
- Asan Medical Center
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell…
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
- Trial name
- NCT07300241
- Testing
- NEO-811
- Where
- 16 sites in United States
- Volunteers
- 30 people
- Sponsor
- Neomorph, Inc
Stomach Neoplasms, Gastric Cancer
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
This study is designed to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with capecitabine plus oxaliplatin (XELOX) for first-line treatment in participants with HER2-negative unresectable…
- Conditions
- Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04933227
- Testing
- Atezolizumab, Tiragolumab, Oxaliplatin
- Where
- 11 sites in China
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Adenocarcinoma of the Prostate
A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel
The primary objective was to evaluate the PSA (biochemical) progression-free survival (PFS) of high-risk metastasis-free PC patients, treated with LH-RH agonist for one year with or without docetaxel after prior radical…
- Trial name
- RisingPSA (NCT00764166)
- Testing
- Docetaxel + hormonal treatment (LH-RH agonist), Hormonal treatment (LH-RH agonist)
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.